Open Daily: 10am - 10pm | Alley door pickup 10am - 7pm 3038 Hennepin Ave Minneapolis, MN
612-822-4611

  • Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Bisphosphonates in Clinical Oncology: The Development of Pamidronate

Bisphosphonates in Clinical Oncology: The Development of Pamidronate

Thürlimann, Beat

Paperback

Series: Recent Results in Cancer Research, Book 149

Medical Reference

ISBN10: 3642641482
ISBN13: 9783642641480
Publisher: Springer
Published: Sep 15 2011
Pages: 113
Weight: 0.43
Height: 0.28 Width: 6.14 Depth: 9.21
Language: English
The book gives an overview of the clinical developments in the use of bisphosphonates in clinical oncology. The first part pre- sents the composition, physiology, and pathophysiology of bone. Next is a section giving insight into mechanisms of bone resorp- tion, bone formation, and bone remodeling, a field in which I was most influenced by O. L. M. Bijvoet and H. Fleisch. The sec- ond part summarizes the pharmacological treatments for disor- ders of bone remodeling. The clinical aspects of tumor-induced hypercalcemia and its management are described in detail, in- cluding our first prospective randomized crossover study testing pamidronate versus mithramycin. The bisphosphonates were in- troduced in clinical oncology by endocrinologists. The same was true for our institution in 1986, when P. Burckhardt proposed testing pamidronate in the above-mentioned trial in his institu- tion (CHUV) and in our department. The impressive results ob- tained in the hypercalcemia trial stimulated our interest, and we actively investigated the use of pamidronate to counteract osteo- lytic bone destruction in cancer patients. These investigations are presented and discussed in the third part. They represent the interdisciplinary work involving many co-workers of the Depart- ment of Internal Medicine C and other institutes of the Interdis- ciplinary Oncology Center St. Gallen (IOSG), which I was privi- leged to chair for 10 years. Initially, a pharmacokinetic study was performed in order to optimize and facilitate the administration of the drug to patients with malignant osteolytic bone disease.

Also in

Medical Reference

View All